Literature DB >> 19859830

Regulating functional cell fates in CD8 T cells.

Protul A Shrikant1, Rajesh Rao, Qingsheng Li, Joshua Kesterson, Cheryl Eppolito, Axel Mischo, Pankaj Singhal.   

Abstract

The attributes of specificity and memory enable CD8(+) T cells to provide long-lasting protection against a variety of challenges. Although, the importance of CD8(+) T cells for protection against intracellular infections and transformation is well-established, the functional type; effector phenotypes (Tc1, Tc2, Tc17 and/or Tcreg) and/or memory (effector or central), of CD8(+) T cells most desirable for tumor immunity is not established. To determine the tumor efficacy of various effector types and/or memory CD8 T cells, it is imperative to better understand intrinsic and extrinsic factors that regulate CD8(+) T cell differentiation and use this information to generate and test distinct functional cell types in tumor models. The focus of our laboratory investigations is to identify the extrinsic factors such as antigen strength, co-stimulatory molecules, cytokines, and small molecule modifiers that regulate intrinsic programs for various effector and/or memory cell fate in antigen specific CD8 T cells. The use of this information to generate immunity in murine tumor models has facilitated development of new adoptive cell transfer (ACT) as well as immunization strategies for cancer treatment.

Entities:  

Mesh:

Year:  2010        PMID: 19859830      PMCID: PMC5049497          DOI: 10.1007/s12026-009-8130-9

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  88 in total

Review 1.  CD8+ T cell effector mechanisms in resistance to infection.

Authors:  J T Harty; A R Tvinnereim; D W White
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

3.  IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion.

Authors:  Warren N D'Souza; Leo Lefrançois
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

4.  CD8+ T cell contraction is controlled by early inflammation.

Authors:  Vladimir P Badovinac; Brandon B Porter; John T Harty
Journal:  Nat Immunol       Date:  2004-07-11       Impact factor: 25.606

5.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

6.  Cutting edge: IL-7-independent regulation of IL-7 receptor alpha expression and memory CD8 T cell development.

Authors:  Kimberly D Klonowski; Kristina J Williams; Amanda L Marzo; Leo Lefrançois
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

7.  CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion.

Authors:  J R Maxwell; J D Campbell; C H Kim; A T Vella
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

8.  Requirement of the IFN-alpha/beta-induced CXCR3 chemokine signalling for CD8+ T cell activation.

Authors:  Kouetsu Ogasawara; Shigeaki Hida; Youmin Weng; Akio Saiura; Kojiro Sato; Hiroshi Takayanagi; Shinya Sakaguchi; Taeko Yokochi; Tatsuhiko Kodama; Makoto Naitoh; Julie A De Martino; Tadatsugu Taniguchi
Journal:  Genes Cells       Date:  2002-03       Impact factor: 1.891

9.  Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells.

Authors:  Susanne J Szabo; Brandon M Sullivan; Claudia Stemmann; Abhay R Satoskar; Barry P Sleckman; Laurie H Glimcher
Journal:  Science       Date:  2002-01-11       Impact factor: 47.728

10.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

Authors:  Matthew A Williams; Aaron J Tyznik; Michael J Bevan
Journal:  Nature       Date:  2006-06-15       Impact factor: 49.962

View more
  22 in total

1.  NKG2D receptor regulates human effector T-cell cytokine production.

Authors:  Amorette Barber; Charles L Sentman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines.

Authors:  Jennifer D Bassett; Stephanie L Swift; Heather VanSeggelen; Joanne A Hammill; A J Robert McGray; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

Review 3.  IL-17 signaling in host defense against Candida albicans.

Authors:  Sarah L Gaffen; Nydiaris Hernández-Santos; Alanna C Peterson
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

4.  CXCR3 expression defines a novel subset of innate CD8+ T cells that enhance immunity against bacterial infection and cancer upon stimulation with IL-15.

Authors:  Steve Oghumu; Cesar A Terrazas; Sanjay Varikuti; Jennifer Kimble; Stephen Vadia; Lianbo Yu; Stephanie Seveau; Abhay R Satoskar
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

5.  Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.

Authors:  Mark P Rubinstein; Ee Wern Su; Samantha Suriano; Colleen A Cloud; Kristina Andrijauskaite; Pravin Kesarwani; Kristina M Schwartz; Katelyn M Williams; C Bryce Johnson; Mingli Li; Gina M Scurti; Mohamed L Salem; Chrystal M Paulos; Elizabeth Garrett-Mayer; Shikhar Mehrotra; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2015-02-13       Impact factor: 6.968

6.  Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

Authors:  Yong Lu; Bangxing Hong; Haiyan Li; Yuhuan Zheng; Mingjun Zhang; Siqing Wang; Jianfei Qian; Qing Yi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

7.  Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation.

Authors:  Bryan McQueen; Kelsey Trace; Emily Whitman; Taylor Bedsworth; Amorette Barber
Journal:  Immunology       Date:  2016-01-17       Impact factor: 7.397

Review 8.  Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.

Authors:  Kinga Majchrzak; Michelle H Nelson; Stefanie R Bailey; Jacob S Bowers; Xue-Zhong Yu; Mark P Rubinstein; Richard A Himes; Chrystal M Paulos
Journal:  Cancer Immunol Immunother       Date:  2016-01-29       Impact factor: 6.968

Review 9.  The effects of TLR activation on T-cell development and differentiation.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Ying-Xiang Yang; Anthony E T Yeo
Journal:  Clin Dev Immunol       Date:  2012-06-07

Review 10.  Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system.

Authors:  Nico Melzer; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2012-09-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.